南美錐蟲病：美國錐蟲病市場

本報告調查了全球南美錐蟲病市場，並提供了市場概況、市場影響因素分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、新藥趨勢、競爭形勢以及主要企業。.進行了總結。

目錄

第1章簡介

第 2 章摘要/亮點

第3章市場概況

• 歷史
• 克氏錐蟲
• 向量和 T. cruzi
• 感染途徑
• 疾病類型
• 前景
• 新藥

第 4 章南美錐蟲病：透過藥物

• 概述
• 苯並硝唑
• 苯並硝唑毒性
• 硝呋替莫
• 硝呋莫司毒性

第 5 章南美錐蟲病：診斷

• 概述
• 血清學（抗體檢測）
• 分子檢測

第6章 競爭形勢

• 競爭分析

第7章 公司簡介

• BAYER AG
• INSUD PHARMA

第 8 章附錄：首字母縮寫詞

Highlights:

The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.

Report Scope:

The current research provides a thorough overview of the CD market. This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis. The scope of this report covers treatment throughout Latin America.

Report Includes:

• An overview of the global chagas disease (T. cruzi infection) market
• Analyses of the global market trends, with historical market revenue from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the market size and revenue forecast for global chagas disease market, and corresponding market share analysis based on the product type, treatment, and region
• Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
• Review of the epidemiology of chagas disease and potential of key marketed drugs and recent approvals
• Discussion of sustainability trends and factors in the chagas disease market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed
• Analysis of the competitive intelligence based on recent developments, key financials and segmental revenues, and product launch strategies
• Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses

Table of Contents

Chapter 1 Introduction

• Overview
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Segmentation Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

• History
• Trypanosoma Cruzi
• Vector and T. cruzi
• Transmission Routes
• Clinical Forms
• Future Perspectives
• Novel Drugs

Chapter 4 Chagas Disease by Drugs

• Overview
• Benznidazole
• Toxicity of Benznidazole
• Nifurtimox
• Toxicity of Nifurtimox

Chapter 5 Chagas Disease by Diagnosis

• Overview
• Serology (Antibody Detection)
• Molecular Testing

Chapter 6 Competitive Landscape

• Competitive Analysis

Chapter 7 Company Profiles

• BAYER AG
• INSUD PHARMA

Chapter 8 Appendix: Acronyms

List of Tables

• Table 1 : Novel Drugs for Chagas Disease Treatment
• Table 2 : Drugs for Chagas Disease
• Table 3 : Bayer AG: Company Snapshot
• Table 4 : Bayer AG: Annual Revenue, 2021 and 2022
• Table 5 : Bayer AG: News
• Table 6 : Insud Pharma: Company Snapshot
• Table 7 : Insud Pharma: News
• Table 8 : Acronyms Used in This Report

List of Figures

• Summary Figure : Life Cycle of Trypanosoma Cruzi
• Figure 1 : Bayer AG: Annual Revenue, 2021 and 2022
• Figure 2 : Bayer AG: Revenue Shares, by Business Unit, 2022
• Figure 3 : Bayer AG: Revenue Shares, by Region, 2022